Companies › Hanlim Pharm.
4 active drug programs in 4 registered trials: 4 Phase 3; Cardiovascular; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HL1113R1 | – | Phase 3 | Hypertension | Dec 2028 |
| HL1113R2 | – | Phase 3 | Hypertension | Dec 2028 |
| HL1113T1 | – | Phase 3 | Hypertension | Dec 2028 |
| HL1113T2 | – | Phase 3 | Hypertension | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07552389 | HL1113T2 | Phase 3 | Hypertension | Cardiovascular | Dec 2028 |
| NCT07552389 | HL1113T1 | Phase 3 | Hypertension | Cardiovascular | Dec 2028 |
| NCT07552389 | HL1113R1 | Phase 3 | Hypertension | Cardiovascular | Dec 2028 |
| NCT07552389 | HL1113R2 | Phase 3 | Hypertension | Cardiovascular | Dec 2028 |
No annotated target.
–
CeleCor Therapeutics MedTrace Pharma SPH Qingdao Growful Pharmacetical Trust Bio-sonics Liquidia Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.